New Pill-Infusion combo takes on Hard-to-Treat cancers

NCT ID NCT06220318

Ongoing Disease control Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the combination can shrink tumors or slow cancer growth. It is an early-stage study, so the main goals are to understand side effects and get a first look at effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C019199 (oral tablet) combined with sintilimab (intravenous infusion)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with only 155 participants, so results may not apply to everyone. The combination may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Hunan Cancer Hospital

Changsha, Hunan, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.